FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Amna Ibrahim et al.|Clinical Cancer Research|2020Cited by 185
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Richard Pazdur, Erik Bloomquist et al.|Clinical Cancer Research|2018Cited by 115